vimarsana.com

ஸ்டெர்லிங் பார்மா தீர்வுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novasep, heeding the next-gen oncology call, boosts high-potency drug ingredient capacity

May 13, 2021 8:59am Novasep recently sold its viral vector manufacturing unit to Thermo Fisher Scientific for $878.2 million in cash. ( Flag of France, Undated (CC BY 2.0) by nathanh100) With so many customers working on cutting-edge cancer treatments, CDMO Novasep says demand for antibody-drug conjugate manufacturing is booming. Heeding the call, Novasep on Wednesday said it plans to beef up capacity for highly potent active pharmaceutical ingredients (HPAPIs) a key component of the treatments at its plant in Le Mans, France. The increase to both clinical and commercial capacity will be fueled by a more than €4 million ($4.83 million) investment and at least 30 new hires at the site. 

IQX Limited (NSX:IQX) Progress of Clinical Programs - ABN Newswire (@ABN_Newswire)

IQX Limited (NSX:IQX) Progress of Clinical Programs    Progress of Clinical ProgramsSydney, April 29, 2021 AEST (ABN Newswire) - iQX Limited (iQX Ltd) ( NSX:IQX) would like to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) in which iQX Ltd holds a 19% equity position, has received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a clinical validation study to test patient samples from a COVID-19 repository. The study follows a partnership with the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss Institute), through Life Science Biosensor Diagnostics Pty Ltd subsidiary, GBS Inc. ( Nasdaq:GBS), a Delaware corporation, to develop a novel diagnostic SARS-CoV-2 test.

ADC Bio acquired, focus on Pfizer, Gilead, AZ, Daiichi deals

Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), has acquired ADC Biotechnology (ADC Bio), a UK based company specializing in antibody-drug conjugates (ADCs). The move was expected; it follows Sterling’s strategic investment in the ADC Bio business back in December 2020, with the CDMO indicating then the possibility it would take on full ownership of the UK firm in early 2021, subject to due diligence. ADC Bio have been at the forefront of antibody-drug bioconjugation and process development in recent years. Its Deeside, Wales, UK facility will rebrand to become part of the Sterling Pharma Solutions international network.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.